Bio-Rad Laboratories, Inc.
NYSEBio-Rad Laboratories heads into the post-earnings stretch with a sharp divergence between what options markets are saying and what short sellers are actually doing. The clearest signal this week is in options. Demand for downside protection has jumped well above normal — the put/call ratio hit 0.55 on Tuesday, more than two and a half standard deviations above its 20-day mean of…
BIO cost to borrow jumps 126% in one week to 0.49%, reflecting tightening borrowing conditions after recent analyst upgrade.
Snapshot as of 6 Aug 2026
Bio-Rad Laboratories heads into the post-earnings stretch with a sharp divergence between what options markets are saying and what short sellers are actually doing. The clearest signal this week is in options. Demand…
Bio-Rad Laboratories reports Q1 2026 results after the close tomorrow, April 30. The stock is down 8.6% on the week to $279.34, falling harder than most peers. The setup heading into the print is defined by one clear…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIO — free to start on ORTEX.
Sign up for free →Open BIO on ORTEX